Lenz Therapeutics, Inc. (NASDAQ: LENZ) has made a significant announcement regarding the commercial availability of its groundbreaking product, Vizz (aceclidine ophthalmic solution) 1.44%. This eye drop, approved by the FDA, is the first of its kind to address presbyopia in adults. The company has commenced the distribution of professional product samples to eye care professionals across the United States, with commercial product shipments set to begin in October 2025.
Vizz is designed to improve near vision in adults with presbyopia for up to 10 hours, a condition that affects approximately 128 million adults in the United States. Leveraging aceclidine, the eye drop offers a unique mechanism of action as a predominantly pupil-selective miotic, interacting with the iris and resulting in a pinhole effect. This effect extends depth of focus, significantly enhancing near vision without causing a myopic shift.
In the clarity phase 3 clinical trial, an impressive 93% of participants achieved 20/40 or better near vision within 30 minutes, which lasted up to 10 hours. This level of near vision can potentially restore the ability to read a phone screen and other everyday fine print without the use of reading glasses.
Lenz Therapeutics is enthusiastic about the reception of Vizz within the eye care professional community and is confident in the product's potential success in the market. The company's President and CEO, Eef Schimmelpennink, expressed excitement over the product's availability, emphasizing the team's extensive preparation for this significant milestone.
Shawn Olsson, the Chief Commercial Officer of Lenz Therapeutics, highlighted the impact of Vizz on individuals living with presbyopia, citing the restoration of everyday confidence and the freedom to engage in daily activities without the hindrance of glasses.
This development signifies a major breakthrough in the treatment of presbyopia, as Vizz provides a simple and fast-acting solution for individuals seeking improved near vision. With the distribution of professional product samples underway and commercial product shipments set to commence, the availability of Vizz represents a significant step forward in addressing the needs of millions of adults impacted by presbyopia in the United States. Today the company's shares have moved 2.9% to a price of $46.19. Check out the company's full 8-K submission here.
